6160 — BeOne Medicines AG Income Statement
0.000.00%
- HK$266.51bn
- HK$237.46bn
- CNY38.22bn
Annual income statement for BeOne Medicines AG, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | CAS | CAS | CAS | CAS | CAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7,589 | 9,566 | 17,423 | 27,214 | 38,225 |
| Cost of Revenue | |||||
| Gross Profit | 6,528 | 7,663 | 14,713 | 22,951 | 33,422 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 17,168 | 22,992 | 26,234 | 31,376 | 35,624 |
| Operating Profit | -9,580 | -13,425 | -8,810 | -4,162 | 2,601 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9,579 | -13,427 | -6,208 | -4,163 | 2,597 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -9,748 | -13,642 | -6,716 | -4,978 | 1,461 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -9,748 | -13,642 | -6,716 | -4,978 | 1,461 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9,748 | -13,642 | -6,716 | -4,978 | 1,461 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -7.3 | -10.2 | -4.95 | -3.66 | 1.01 |
| Dividends per Share |